Core Insights - BioHarvest Sciences reported a robust 41% year-over-year revenue growth for Q2 2025, reaching $8.5 million, driven by strong sales in its core VINIA® capsule business and new product launches [4][6] - The company aims to achieve adjusted EBITDA breakeven by Q4 2025, supported by continued growth in its product lines and a strong CDMO pipeline [3][4] Financial Performance - Total revenues for Q2 2025 increased to $8.5 million from $6.0 million in Q2 2024, with gross margins expanding by 800 basis points to 60% [4][6] - Gross profit rose 65% to $5.1 million, attributed to increased manufacturing scale and improved yields [7] - Operating expenses increased to $6.9 million from $4.8 million year-over-year, primarily due to higher marketing spend and costs associated with the CDMO services division [8] Net Loss and Cash Position - The net loss for Q2 2025 was $4.0 million, or $0.24 per share, compared to a net loss of $0.7 million, or $0.04 per share, in Q2 2024 [9] - Cash and cash equivalents as of June 30, 2025, totaled $3.7 million, up from $2.4 million at the end of 2024 [10] Product and Market Developments - The company has launched new products, including VINIA® Daily Chews 2X Formula, and secured a new CDMO contract for developing a plant-based fragrance compound [4][13] - Management expects to launch additional products and CDMO services in the second half of 2025, including an electrolyte drink targeting the $13 billion hydration market [4][13] Strategic Initiatives - BioHarvest is focusing on three growth initiatives: expanding its Health Pros affiliate program, launching a new electrolyte drink, and introducing an AI-enabled CDMO discovery phase [13] - The company continues to position its botanical synthesis technology as a commercial engine for high-value plant-based compounds [5]